ARS Pharmaceuticals, Inc. (SPRY)
NasdaqGM: SPRY
· 即時價格 · USD
5.82
+0.05 (0.87%)
收盤價： Sep 02, 2026, 3:59 PM
股價、關鍵數字和最新消息，都在這一頁。
ARS Pharmaceuticals, Inc.（SPRY）股價、分析與資料
0.87% (1D)
| 買價 | 3.89 |
| 市值 | 579M |
| 營收 (ttm) | 117M |
| 淨利（ttm） | -215M |
| 0.97 | |
| -2.19 | |
| n/a | |
| -6.54 | |
| P/B (ttm) | 46.19 |
| P/S (ttm) | 4.95 |
| 財報日期 | Nov 10, 2026 |
| 賣價 | 6.72 |
| 成交量 | 1,196,656 |
| 20 日平均成交量 | 2,017,466 |
| 開盤價 | 5.86 |
| 前收盤價 | 5.77 |
| 當日區間 | 5.75 - 6.00 |
| 52 週範圍 | 4.91 - 13.15 |
| 分析師 | n/a |
| 目標價 | 23 (295.19%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 SPRY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California....
完整的公司簡介財務表現
ARS Pharmaceuticals 在 2025 年的營收為 84.28M，較前一年的 89.15M 減少 -5.46%。 淨利為 -171.3M，較前期減少 -2,241.76%。
財務報表財報驚奇
ARS Pharmaceuticals 已於 Aug 13, 2026 公布季度財報：
- 營收為 $22.68M 低於預期 $0, 年增 184.47% 成長.
- 每股盈餘為 -0.63 低於預期 -0.14, 年增 -36.96% 下滑.
第 1 頁，共 2 頁